JP2021167324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021167324A5 JP2021167324A5 JP2021103895A JP2021103895A JP2021167324A5 JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5 JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- molecule
- composition according
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175024P | 2015-06-12 | 2015-06-12 | |
| US201562175044P | 2015-06-12 | 2015-06-12 | |
| US62/175,024 | 2015-06-12 | ||
| US62/175,044 | 2015-06-12 | ||
| US201562257852P | 2015-11-20 | 2015-11-20 | |
| US62/257,852 | 2015-11-20 | ||
| US201662321724P | 2016-04-12 | 2016-04-12 | |
| US62/321,724 | 2016-04-12 | ||
| JP2017563600A JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Division JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021167324A JP2021167324A (ja) | 2021-10-21 |
| JP2021167324A5 true JP2021167324A5 (https=) | 2021-12-23 |
Family
ID=57504236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Pending JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
| JP2021103895A Pending JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Pending JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180312561A1 (https=) |
| EP (1) | EP3307301A4 (https=) |
| JP (2) | JP2018516950A (https=) |
| AU (2) | AU2016274897B2 (https=) |
| CA (1) | CA2988619A1 (https=) |
| WO (1) | WO2016201251A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| CN110194800B (zh) * | 2018-02-26 | 2022-11-18 | 张灏 | 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| AU2022284372A1 (en) * | 2021-06-03 | 2023-12-14 | Bristol-Myers Squibb Company | Neodegrader-anti-cd33 antibody conjugates |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
| CN101868246A (zh) * | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US9272029B2 (en) * | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| EP2582727B8 (en) * | 2010-06-16 | 2017-04-19 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Antibodies to endoplasmin and their use |
| US9534056B2 (en) * | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| EP3559049B1 (en) * | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| PT2822575T (pt) * | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2016
- 2016-06-10 JP JP2017563600A patent/JP2018516950A/ja active Pending
- 2016-06-10 EP EP16808391.3A patent/EP3307301A4/en not_active Withdrawn
- 2016-06-10 CA CA2988619A patent/CA2988619A1/en not_active Abandoned
- 2016-06-10 AU AU2016274897A patent/AU2016274897B2/en not_active Ceased
- 2016-06-10 US US15/735,583 patent/US20180312561A1/en not_active Abandoned
- 2016-06-10 WO PCT/US2016/036925 patent/WO2016201251A1/en not_active Ceased
-
2021
- 2021-05-13 AU AU2021203042A patent/AU2021203042A1/en not_active Abandoned
- 2021-06-23 JP JP2021103895A patent/JP2021167324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021167324A5 (https=) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP2020515247A5 (https=) | ||
| JP2019511212A (ja) | ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体 | |
| US20180044428A1 (en) | Compositions and methods for enhancing the efficacy of cancer therapy | |
| JP2018516950A5 (https=) | ||
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP7606706B2 (ja) | ヒトネクチン－２に特異的な抗体 | |
| JP7809635B2 (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| WO2019206095A1 (zh) | 针对tim-3的抗体及其用途 | |
| WO2023166210A1 (en) | Anti pd-l2 antibody | |
| EP4263584A1 (en) | Combination therapy for the treatment of cancer | |
| US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
| WO2020123477A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| JP2022513246A (ja) | 抗ｃｅａｃａｍ６及びｔｉｍ３抗体の医薬組み合わせ | |
| JP2022513036A (ja) | がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ | |
| WO2023146394A1 (en) | Combination therapy for the treatment of cancer | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| JP7684656B2 (ja) | 免疫抑制剤 | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| US20240067741A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| US20220169736A1 (en) | Combinations of anti-ildr2 antibodies and pd-1 antagonists | |
| TW202612728A (zh) | 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法 |